Corautus Genetics Inc. to Host Conference Call on May 15, 2006
May 08 2006 - 9:00AM
PR Newswire (US)
ATLANTA, May 8 /PRNewswire-FirstCall/ -- Corautus Genetics Inc.
(NASDAQ:VEGF), a biopharmaceutical company dedicated to the
development of innovative gene transfer therapy products for the
treatment of cardiovascular (severe angina) and peripheral vascular
disease, will release its first quarter 2006 financial results on
Monday, May 15, 2006. Corautus will also host a conference call to
discuss the results and provide an update of its therapeutic
development program at 11:00 A.M. Eastern time on May 15. Richard
Otto, President and Chief Executive Officer of Corautus, will host
the call. To access the live webcast, please log on to the
Corautus' website at http://www.corautus.com/ and go to the
Investor Relations section. Alternatively, domestic callers may
participate in the conference call by dialing (888) 396- 2356, and
international callers may participate in the conference call by
dialing (617) 847-8709. The participant passcode for access to the
conference is "Corautus". Webcast and telephone replays of the
conference call will be available approximately two hours after the
completion of the call. Domestic callers can access the replay by
dialing (888) 286-8010, and international callers can access the
replay by dialing (617) 801-6888; the PIN access number is
56918015. About Corautus Genetics Inc. Corautus Genetics Inc. is a
clinical-stage biopharmaceutical company dedicated to the
development of gene transfer therapy products for the treatment of
cardiovascular (severe angina) and peripheral vascular disease.
Corautus is currently developing and testing a gene transfer
product using the Vascular Endothelial Growth Factor-2 (VEGF-2)
gene to promote therapeutic angiogenesis in ischemic muscle.
Corautus has a strategic alliance with Boston Scientific
Corporation to develop, commercialize and distribute the VEGF-2
gene therapy products. For more information, please visit
http://www.corautus.com/. Forward-Looking Statement This press
release may contain forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Such statements are subject to certain factors, risks
and uncertainties that may cause actual results, events and
performances to differ materially from those referred to in such
statements. These risks include statements that address operating
performance, events or developments that we expect or anticipate
will occur in the future, such as projections about our GENASIS
clinical trial or any future trials, including the likelihood of
obtaining positive data from such trials, potential benefits from
manufacturing agreements, the potential benefits from previous
clinical trials, potential benefits from Phase I trials we are
supporting in the areas of critical limb ischemia and diabetic
neuropathy, future results of operations or our financial
condition, adequacy of funding, benefits from the alliance with
Boston Scientific, research, development and commercialization of
our product candidates, anticipated trends in our business,
manufacture of sufficient and acceptable quantities of our proposed
products, approval of our product candidates, meeting additional
capital requirements, and other risks that could cause actual
results to differ materially. These risks are discussed in Corautus
Genetics Inc.'s Securities and Exchange Commission filings,
including, but not limited to, the risk factors in Corautus' 2005
Annual Report on Form 10-K which was filed on March 20, 2006. All
forward-looking statements included in this document are based on
information available to Corautus on the date hereof, and Corautus
assumes no obligation to update any such forward-looking
statements. Company Contact: Michael K. Steele (404) 526-6212
Investor Relations Contacts: Lippert/Heilshorn & Associates Kim
Sutton Golodetz Anne Marie Fields 212-838-3777 DATASOURCE: Corautus
Genetics Inc. CONTACT: Michael K. Steele of Corautus Genetics Inc.,
+1-404-526-6212, or ; or Investor Relations, Kim Sutton Golodetz, ,
or Anne Marie Fields, , of Lippert-Heilshorn & Associates,
+1-212-838-3777 Web Site: http://www.corautus.com/
Copyright
Corautus Genetics (NASDAQ:VEGF)
Historical Stock Chart
From Apr 2024 to May 2024
Corautus Genetics (NASDAQ:VEGF)
Historical Stock Chart
From May 2023 to May 2024